Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Recurrence × Hydroxyurea × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1 Carcinoma, Squamous Cell 1

Interventions

Temozolomide 3 Gemcitabine 3 Etoposide 3 pembrolizumab 2 Rituximab 2 Lomustine 2 Haloperidol 2 Dexamethasone 2 Cyclosporine 2 vocimagene amiretrorepvec 1 trofosfamide 1 tinostamustine 1 selinexor 1 ruxolitinib 1 regorafenib 1 peginterferon alfa-2b 1 osimertinib 1 menatetrenone 1 interferon gamma-1b 1 interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1 imetelstat 1 glumetinib 1 fludarabine 1 etoposide phosphate 1 eculizumab 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 carbon-11 acetate 1 blinatumomab 1 auricularum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01211938 2017-05-16

JANORL2

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2/3 Completed

Carcinoma, Squamous Cell, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡